Oncotelic Therapeutics, Inc. Operating Income Loss

• Oncotelic Therapeutics, Inc. showed an increase of +46.2% in Operating Income Loss from 2023 to 2024.
• This data is from Oncotelic Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
• XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2009 to 2024), Oncotelic Therapeutics, Inc.'s Operating Income Loss has grown by 88.5%.
• Historical annual values: Fiscal year 2024: -$3.58 million | Fiscal year 2023: -$6.65 million | Fiscal year 2022: -$9.72 million | Fiscal year 2021: -$9.13 million | Fiscal year 2020: -$7.58 million | Fiscal year 2019: -$4.31 million | Fiscal year 2018: -$712.7 thousand | Fiscal year 2017: -$13.84 million | Fiscal year 2016: -$13.76 million | Fiscal year 2015: -$13.68 million | Fiscal year 2014: -$12.65 million | Fiscal year 2013: -$8.28 million | Fiscal year 2012: -$8.07 million | Fiscal year 2011: -$11.89 million | Fiscal year 2010: -$18.51 million | Fiscal year 2009: -$31.16 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026